266 related articles for article (PubMed ID: 37402886)
1. Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study.
Athanassiou P; Psaltis D; Georgiadis A; Katsifis G; Theodoridou A; Gazi S; Sidiropoulos P; Tektonidou MG; Bounas A; Kandyli A; Vounotrypidis P; Sakellariou GT; Vassilopoulos D; Huang Z; Petrikkou E; Boumpas D
Rheumatol Int; 2023 Oct; 43(10):1871-1883. PubMed ID: 37402886
[TBL] [Abstract][Full Text] [Related]
2. The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the 'GO-UP' study.
Athanassiou P; Kotrotsios A; Kallitsakis I; Bounas A; Dimitroulas T; Garyfallos A; Tektonidou MG; Vosvotekas G; Livieratos A; Petrikkou E; Katsifis G
Qual Life Res; 2022 May; 31(5):1385-1399. PubMed ID: 34839451
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α inhibitor therapy: a pooled analysis of European prospective observational studie.
Govoni M; Batalov A; Boumpas DT; D'Angelo S; De Keyser F; Flipo RM; Kellner H; Leroi H; Khalifa A
Clin Exp Rheumatol; 2024 Mar; 42(3):642-650. PubMed ID: 37976120
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study.
D'Angelo S; Tirri E; Giardino AM; Mattucci-Cerinic M; Dagna L; Santo L; Ciccia F; Frediani B; Govoni M; Bobbio Pallavicini F; Grembiale RD; Delle Sedie A; Mulè R; Cantatore FP; Foti R; Gremese E; Conigliaro P; Salaffi F; Viapiana O; Cauli A; Giacomelli R; Arcarese L; Guggino G; Russo R; Puenpatom A; Capocotta D; Nacci F; Anelli MG; Picerno V; Binetti C; Iannone F
J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887946
[TBL] [Abstract][Full Text] [Related]
5. A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE Study.
Dejaco C; Mueller T; Zamani O; Kurtz U; Egger S; Resch-Passini J; Totzauer A; Yazdani-Biuki B; Schwingenschloegl T; Peichl P; Kraus A; Naerr GW
Front Med (Lausanne); 2022; 9():881943. PubMed ID: 35721062
[TBL] [Abstract][Full Text] [Related]
6. The effects of golimumab on patient centric outcomes amongst rheumatoid arthritis patients in Greece. The GO-Q study.
Psaltis D; Settas L; Georgiadis A; Koukli E; Bounas A; Livieratos A; Petrikkou E; Kalogiannaki H; Repa A; Vassilopoulos D; Sidiropoulos P
Rheumatol Int; 2022 Apr; 42(4):639-650. PubMed ID: 35091757
[TBL] [Abstract][Full Text] [Related]
7. Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study.
Gossec L; Siebert S; Bergmans P; de Vlam K; Gremese E; Joven-Ibáñez B; Korotaeva TV; Lavie F; Noël W; Nurmohamed MT; Sfikakis PP; Sharaf M; Theander E; Smolen JS
Arthritis Res Ther; 2023 Jun; 25(1):109. PubMed ID: 37353788
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.
Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
Rheumatol Int; 2019 Jan; 39(1):131-140. PubMed ID: 30415451
[TBL] [Abstract][Full Text] [Related]
9. Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.
Michielsens CAJ; den Broeder N; Mulder MLM; van den Hoogen FHJ; Verhoef LM; den Broeder AA
Rheumatology (Oxford); 2022 May; 61(6):2307-2315. PubMed ID: 34599803
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany.
Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
BMJ Open; 2018 Jun; 8(6):e021082. PubMed ID: 29903793
[TBL] [Abstract][Full Text] [Related]
11. Real-life golimumab persitence in patients with axial spondyloarthritis: post-hoc results of the prospective observational cohort study, GO-PRACTICE.
Goupille P; Bertin P; Tubach F; Lespessailles E; Harid N; Sequeira S; Fayette JM; Fautrel B; Flipo RM
Clin Exp Rheumatol; 2022 Jul; 40(7):1352-1360. PubMed ID: 34936548
[TBL] [Abstract][Full Text] [Related]
12. High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry.
Fornaro M; Righetti G; Abbruzzese A; Lopalco G; Cacciapaglia F; Anelli MG; Venerito V; Iannone F
Clin Rheumatol; 2021 Sep; 40(9):3659-3665. PubMed ID: 33864158
[TBL] [Abstract][Full Text] [Related]
13. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.
Egeberg A; Rosenø NAL; Aagaard D; Lørup EH; Nielsen ML; Nymand L; Kristensen LE; Thyssen JP; Thomsen SF; Cordtz RL; Loft N; Skov L; Bryld LE; Rasmussen MK; Højgaard P; Kristensen S; Dreyer L
Semin Arthritis Rheum; 2022 Apr; 53():151979. PubMed ID: 35183936
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry.
Pombo-Suarez M; Sanchez-Piedra C; Garcia-Magallón B; Pérez-Gómez A; Manrique-Arija S; Martín-Doménech R; Colazo M; Campos C; Campos J; Del Pino-Montes J; Arteaga MJ; Cea-Calvo L; Díaz-González F; Gómez-Reino JJ
Clin Rheumatol; 2021 Oct; 40(10):3979-3988. PubMed ID: 33907904
[TBL] [Abstract][Full Text] [Related]
15. Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases.
Pombo-Suárez M; Seoane-Mato D; Díaz-González F; Sánchez-Alonso F; Sánchez-Jareño M; Cea-Calvo L; Castrejón I
Adv Rheumatol; 2023 Jun; 63(1):25. PubMed ID: 37287051
[TBL] [Abstract][Full Text] [Related]
16. Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study.
Karadag O; Dalkilic E; Ayan G; Kucuksahin O; Kasifoglu T; Yilmaz N; Koca SS; Yazisiz V; Erten PT; Sayarlioglu M; Terzioglu ME; Erten S; Kalyoncu U
Clin Rheumatol; 2022 Jan; 41(1):85-94. PubMed ID: 34477993
[TBL] [Abstract][Full Text] [Related]
17. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2018 Dec; 20(1):275. PubMed ID: 30545393
[TBL] [Abstract][Full Text] [Related]
18. Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Iannone F; Santo L; Anelli MG; Bucci R; Semeraro A; Quarta L; D'Onofrio F; Marsico A; Carlino G; Casilli O; Cacciapaglia F; Zuccaro C; Falappone PC; Cantatore FP; Muratore M; Lapadula G
Semin Arthritis Rheum; 2017 Aug; 47(1):108-114. PubMed ID: 28216195
[TBL] [Abstract][Full Text] [Related]
19. Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE.
Feist E; Baraliakos X; Behrens F; Thaçi D; Plenske A; Klaus P; Meng T
Rheumatol Ther; 2024 Apr; 11(2):331-348. PubMed ID: 38308727
[TBL] [Abstract][Full Text] [Related]
20. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
